Future of Clinical Trials, $18m Series A and Breaking Bottlenecks - Meri Beckwith (Lindus Health)
In this week’s episode Meri shares his journey from the world of investing to breaking the bottlenecks when it comes to clinical trials as he builds the anti-CRO for life science pioneers.
We discussed:
🔄 Transitioning from venture capital into healthtech
💼 Investor vs Founder Traits, Personality and Mindset
🌱 The origin story of Lindus Health
🏗️ The first few days/weeks of building Lindus Health
🚧 Barriers to entering the pharma industry as a new startup
🔒 Securing the first clinical trial with Habitual
🍾 The bottle necks of clinical trials
🔍 The process of recruiting patients for clinical trials
❌ Where central organisations and institutions go wrong for clinical trials
🤖 The role of AI in the pharma industry
💰 Fundraising a $18m Series A with investments from the likes of Peter Thiel
🔒 How to prevent being replaced by the board and investors
🏢 How to build a healthy culture and team
🤝 How to become a great CEO and deal with co-founder conflicts
💊 Why do pharma need CROs for clinical trials and why become the anti-CRO
Meri Beckwith is the co-founder of Lindus Health and previously a venture capital investor and partner to biotech and digital health companies. He took part in the COVID-19 vaccine trials as a volunteer, where he saw trail outcomes could be improved by focusing on patient experience.
🚀 Sign up now at https://peerr.io/
🚀 Join over 4,000+ thought leaders, industry experts and deep knowledge creators in health and life sciences
About Us:
We are both Doctors working in London, Co-hosts of the Scrubbed In Show and the Co-founders of Peerr, where we help connect the health and life sciences industry through content.
🎙️ The Scrubbed In Show - Sharing the Stories of Incredible People in Healthcare
https://apple.co/3sfsubf (Apple)
https://spoti.fi/2LoV4X5 (Spotify)
Socials:
📸 / scrubbedin_
🐦 / scrubbedin_
#pharma #lifescience #healthcare #clinicaltrials